Clinical trial registry record

Using panitumumab with ranibizumab injected into the eye to treat exudative age-related macular degeneration

A registered Phase II study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Recruiting.
Evidence
Registered phase ii study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated December 27, 2023.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
ISRCTN85022211
Last registry update
December 27, 2023
Status
Recruiting
Phase
Phase II
Sponsor
Ufa Eye Research Institute
Enrollment
200
Countries
Russian Federation
Match confidence
100%
Source feed
ISRCTN Registry
Automated source synopsis

A registered Phase II study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase II
Study design
Interventional
Evidence population
Human clinical study registration
Participants
200
Population
All · Adult
Duration
2023-12-01 to 2026-12-31
Intervention
Panitumumab; Drug
Comparator
Not reported
Outcomes measured
1. Change in the retinal thickness in the foveola, as measured from Bruch´s membrane to the inner limiting membrane (i.…; At baseline, at the time of the injections and re-injections, and at study end using optical coherence tomography: 1. A…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase IIA trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as Interventional.

Automated source check 98% · update recency 65%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON